person · Reporting owner

SIEGEL SUSAN E

Disclosed activity across 3 companies

Tapewire entity: 44859
SEC CIK: 0001240363

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALIGN TECHNOLOGY INCALGN · Entity 3488	Director	May 20, 2026	May 22, 2026
ILLUMINA, INC.ILMN · Entity 3137	Director	May 21, 2026	May 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALIGN TECHNOLOGY INC

Report date May 20, 2026 · Filed May 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,723	Reported balance After 2026-05-20 transaction · row 1 1 source row Row 1 · 2026-05-20 · Exercise / conversion · Acquired 1,745 · Balance 10,723
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-20 · Exercise / conversion · Disposed 1,745 · Balance 0 F1: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	1,836	Reported balance After 2026-05-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-20 · Grant · Acquired 1,836 · Balance 1,836 F2: 100% of the RSUs granted on May 20, 2026 will become vested on the earlier of (i) May 20, 2027 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person.

F2: 100% of the RSUs granted on May 20, 2026 will become vested on the earlier of (i) May 20, 2027 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date.

ILLUMINA, INC.

Report date May 21, 2026 · Filed May 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	16,535	Reported balance After 2026-05-21 transaction · row 1 1 source row Row 1 · 2026-05-21 · Grant · Acquired 2,072 · Balance 16,535 F1: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date.
Common StockSEC Table I · non-derivative	IndirectReed-Siegel Revocable Trust	4,006	Reported balance Holding disclosure · report date 2026-05-21 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 4,006

Filing footnotes · ownership attribution and instrument terms

F1: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

NEVRO CORP

Report date April 03, 2025 · Filed April 03, 2025

Section 16 reporting ended · disclosed 2025-04-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-04-03 transaction · row 1 1 source row Row 1 · 2025-04-03 · Disposition to issuer · Disposed 24,579 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2025-04-03 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-04-03 · Disposition to issuer · Disposed 7,382 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. F3: Shares held by Bob Reed and Susan Siegel as trustees of the Reed-Siegel Revocable Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time").

F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.

F3: Shares held by Bob Reed and Susan Siegel as trustees of the Reed-Siegel Revocable Trust.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 17, 2017 Filed May 18, 2017 23:22 UTC	ALIGN TECHNOLOGY INC ALGN · Entity 3488	Exercise / conversionRestricted Stock Unit · Derivative	814	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001288257-17-000009 · primary_doc.xml · derivative · entry 2 SIEGEL SUSAN E · CIK 0001240363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 814 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents par value of ALGN common stock F2 · derivative.exercise_date: 100% of the restricted stock unit granted on March 20, 2017 became vested on May 17, 2017 and shares were delivered to reporting person on May 17, 2017. F2 · derivative.expiration_date: 100% of the restricted stock unit granted on March 20, 2017 became vested on May 17, 2017 and shares were delivered to reporting person on May 17, 2017. Read SEC document
May 17, 2017 Filed May 18, 2017 23:22 UTC	ALIGN TECHNOLOGY INC ALGN · Entity 3488	Exercise / conversionCommon Stock	814	$0.00	$0.00	Disclosure SEC source: 0001288257-17-000009 · primary_doc.xml · nonDerivative · entry 1 SIEGEL SUSAN E · CIK 0001240363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 20, 2017 Filed Mar 21, 2017 23:48 UTC	ALIGN TECHNOLOGY INC ALGN · Entity 3488	GrantRestricted Stock Unit · Derivative	814	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001651847-17-000004 · primary_doc.xml · derivative · entry 1 SIEGEL SUSAN E · CIK 0001240363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 814 Underlying: Common Stock · 814 shares Expires not disclosed F1 · derivative.exercise_price: Represents par value of ALGN common stock F2 · derivative.exercise_date: 100% of the restricted stock unit will become vested on May 17, 2017. Shares will be delivered to reporting person on the vest date. F2 · derivative.expiration_date: 100% of the restricted stock unit will become vested on May 17, 2017. Shares will be delivered to reporting person on the vest date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.